Figure 7
VEGFR2 and EGFR relative gene expression in HepG2 cancer treated cells. The effect of treatment with sorafenib in the presence and absence of bevacizumab on the relative expression of VEGFR2 and in the presence and absence of panitumumab on the relative expression of EGFR in HepG2 cancer cells determined by RT-PCR. Each value represents the mean ± SD (n = 3). *P < 0.05 compared to the untreated HepG2 cancer cells (control). #P < 0.05, compared to sorafenib treated HepG2 cancer cells.
